CAJ | 학술논문

目的：观察阿达木单抗治疗对中重度类风湿关节炎患者生存质量的影响。方法：前12周为随机、双盲、安慰剂对照临床研究，后12周为开放研究。302例活动性类风湿关节炎患者接受前12周阿达木单抗40 mg、80 mg或安慰剂的治疗，隔周皮下给药，所有受试者在12~24周接受隔周皮下给药40 mg的阿达木单抗治疗，在干预前和干预后采用SF-36生存质量量表对患者的生存质量进行评定和比较。结果：干预后本组SF-36生存质量量表得分在生理功能、生理职能、躯体疼痛、总体健康、活力、社会功能、情感职能、精神健康8个维度较干预前有明显的提高。结论：阿达木单抗有利于改善类风湿关节炎患者的生存质量。
목적：관찰아체목단항치료대중중도류풍습관절염환자생존질량적영향。방법：전12주위수궤、쌍맹、안위제대조림상연구，후12주위개방연구。302례활동성류풍습관절염환자접수전12주아체목단항40 mg、80 mg혹안위제적치료，격주피하급약，소유수시자재12~24주접수격주피하급약40 mg적아체목단항치료，재간예전화간예후채용SF-36생존질량량표대환자적생존질량진행평정화비교。결과：간예후본조SF-36생존질량량표득분재생리공능、생리직능、구체동통、총체건강、활력、사회공능、정감직능、정신건강8개유도교간예전유명현적제고。결론：아체목단항유리우개선류풍습관절염환자적생존질량。
Objective:To explore the effect of adalimumab on quality of life (QOL) of patients with moderate to severe rheumatoid arthritis. Methods:A total of 302 patients with rheumatoid arthritis were given adalimumab intervention for 24 weeks. A randomized, double-blind placebo-controlled study was carried out in the ifrst 12 weeks, and the patients were divided into three groups, adalimumab 40 mg group, adalimumab 80 mg group, placebo group. The following 12 weeks was a open study, all the patients received subcutaneous administration of adalimumab 40 mg, once every two weeks. The QOL of each patient before and after intervention was assessed and compared by using SF-36 scale. Results:After intervention, physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health were improved signiifcantly. Conclusion:Adalimumab helps to improve the QOL of patients with rheumatoid arthritis.